JPRN-UMIN000030098招募中3 期
Randomized phase III study to evaluate the value of omission of prophylactic neck dissection for stage I/II tongue cancer (JCOG1601, RESPOND) - Randomized phase III study to evaluate the value of omission of prophylactic neck dissection for stage I/II tongue cancer (JCOG1601, RESPOND)
Japan Clinical Oncology Group (JCOG)0 个研究点目标入组 440 人开始时间: 2017年11月24日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 440
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)Synchronous or metachronous (within 5 years) malignancy except cancer with 5-year relative survival rate of 95% or more such as carcinoma in situ, intramucosal tumor, or early stage cancers. 2)Active infection requiring systemic therapy 3)Body temperature >= 38 degrees Celsius 4)Women during pregnancy, within 28 days of postparturition, or during lactation. Men favoring gestation of their partners. 5)Severe psychiatric disease 6)Patients requiring systemic steroid medication or the other immunosuppressive drug excluding corticosteroid drugs.
研究者
相似试验
进行中（未招募）
1 期
A Randomized, Controlle, Phase 3 study to evaluete the efficacy, safety and pharmacokinetics of Melphalan/HDS treatment in Patients with cancer of the eye that has spread to the liverHepatic-Dominant Ocular MelanomaMedDRA version: 20.0Level: PTClassification code 10068117Term: Metastatic ocular melanomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2015-000417-44-ITDELCATH SYSTEMS, INCORPORATIONS240
进行中（未招募）
1 期
A Randomized, Controlled, Phase 3 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Melphalan/HDS Treatment in Patients with cancer of the eye that has spread to the liverEUCTR2015-000417-44-ESDelcath Systems, Ltd240
进行中（未招募）
不适用
Study to evaluate optimized retreatment and prolonged therapy with bortezomibMedDRA version: 17.1Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864Multiple MyelomaEUCTR2011-004795-11-NLJanssen-Cilag International N.V.240
进行中（未招募）
不适用
Study to evaluate optimized retreatment and prolonged therapy with bortezomibMedDRA version: 17.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864Multiple MyelomaEUCTR2011-004795-11-BEJanssen-Cilag International N.V.240
进行中（未招募）
1 期
Study to evaluate optimized retreatment and prolonged therapy with bortezomibMedDRA version: 17.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864Multiple MyelomaEUCTR2011-004795-11-DEJanssen-Cilag International N.V.240